Department of Biomedical Science, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Malaysia.
Department of Biomedical Engineering, Faculty of Engineering, University of Isfahan, Isfahan, Iran.
Mol Biol Rep. 2024 Oct 30;51(1):1103. doi: 10.1007/s11033-024-10034-5.
Despite recent advancements in the treatment of metastatic castrate-resistant prostate cancer (mCRPC), this disease remains lethal. A novel family of targeted pharmaceuticals known as poly-ADP-ribose polymerase (PARP) inhibitors has been developed to treat mCRPC patients with homologous recombination repair (HRR) gene alterations. The FDA recently approved olaparib and rucaparib for treating mCRPC patients with HRR gene alterations. Ongoing trials are investigating combination therapies involving PARP inhibitors combined with radiation, chemotherapy, immunotherapy, and androgen receptor signaling inhibitors (ARSIs) to improve the effectiveness of PARP inhibitors and broaden the range of patients who can benefit from the treatment. This review provides an overview of the development of PARP inhibitors in prostate cancer and analyzes the mechanisms underlying their resistance.
尽管转移性去势抵抗性前列腺癌（mCRPC）的治疗最近取得了进展，但这种疾病仍然是致命的。一类新的靶向药物，即聚 ADP-核糖聚合酶（PARP）抑制剂，已被开发用于治疗同源重组修复（HRR）基因突变的 mCRPC 患者。FDA 最近批准奥拉帕利和芦卡帕利用于治疗 HRR 基因突变的 mCRPC 患者。正在进行的试验正在研究 PARP 抑制剂联合放疗、化疗、免疫疗法和雄激素受体信号抑制剂（ARSIs）的联合治疗方法，以提高 PARP 抑制剂的疗效，并扩大受益于治疗的患者范围。本文综述了 PARP 抑制剂在前列腺癌中的发展，并分析了其耐药机制。
